ImmunoPET: IMaging of cancer imMUNOtherapy targets with positron Emission Tomography: a phase 0/1 study characterising PD-L1 with
Nuclear radiology
Radiation oncology
Respiratory tract tumours
Journal
BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874
Informations de publication
Date de publication:
18 11 2022
18 11 2022
Historique:
entrez:
18
11
2022
pubmed:
19
11
2022
medline:
23
11
2022
Statut:
epublish
Résumé
ImmunoPET is a multicentre, single arm, phase 0-1 study that aims to establish if The phase 0 study recruited 5 PD-L1+ patients with metastatic non-small cell lung cancer (NSCLC). Patients received 60MBq/70 kg This phase 0 study has ethics approval (HREC/65450/PMCC 20/100) and is registered on the Australian Clinical Trials Network (ACTRN12621000171819). The protocol, technical and clinical data will be disseminated by conference presentations and publications. Any modifications to the protocol will be formally documented by administrative letters and must be submitted to the approving HREC for review and approval. Australian Clinical Trials Network ACTRN12621000171819.
Sections du résumé
BACKGROUND
ImmunoPET is a multicentre, single arm, phase 0-1 study that aims to establish if
METHODS
The phase 0 study recruited 5 PD-L1+ patients with metastatic non-small cell lung cancer (NSCLC). Patients received 60MBq/70 kg
ETHICS AND DISSEMINATION
This phase 0 study has ethics approval (HREC/65450/PMCC 20/100) and is registered on the Australian Clinical Trials Network (ACTRN12621000171819). The protocol, technical and clinical data will be disseminated by conference presentations and publications. Any modifications to the protocol will be formally documented by administrative letters and must be submitted to the approving HREC for review and approval.
TRIAL REGISTRATION NUMBER
Australian Clinical Trials Network ACTRN12621000171819.
Identifiants
pubmed: 36400733
pii: bmjopen-2021-056708
doi: 10.1136/bmjopen-2021-056708
pmc: PMC9677006
doi:
Substances chimiques
B7-H1 Antigen
0
durvalumab
28X28X9OKV
Banques de données
ANZCTR
['ACTRN12621000171819']
Types de publication
Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e056708Informations de copyright
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: FH-J has clinical trial funding, has received honoraria and participated in advisory boards for Astra Zeneca. She has received payments and honoria from BeiGene and MSD for lectures and presentations. Her work is supported by the Peter Mac Foundation and the Victorian Cancer Agency. SER and PSD are inventors on intellectual property relating to the use of DFOSq that have been licensed from the University of Melbourne to Telix Pharmaceuticals. TJ has received payments and honoraria from BMS and Astra Zeneca for lectures and presentations, and sits on Data Safety and Monitoring Boards or Advisory boards for Roche, BMS, Astra Zeneca, Novartis, Amgen, Puma, MSD and Merck. SF has received payments and honoraria from Astra Zeneca, Roche, Amgen, Novartis, Bayer, GSK, BMS, MSD and Janssen for lectures and presentations. KB has received payments and honoraria from Bayer and Abbvie for lectures and presentations and participates on Data Safety and Monitoring boards for Novartis.
Références
N Engl J Med. 2017 Nov 16;377(20):1919-1929
pubmed: 28885881
J Nucl Med. 2022 Mar;63(3):362-367
pubmed: 34272316
N Engl J Med. 2017 Oct 5;377(14):1345-1356
pubmed: 28889792
Nat Med. 2018 Dec;24(12):1852-1858
pubmed: 30478423
N Engl J Med. 2015 Jul 9;373(2):123-35
pubmed: 26028407
J Nucl Med. 2022 May;63(5):720-726
pubmed: 34413145
Cancer Res. 2017 Jun 1;77(11):2893-2902
pubmed: 28572504
Cancer Lett. 2015 Nov 28;368(2):185-90
pubmed: 25799953
Nat Commun. 2018 Nov 7;9(1):4664
pubmed: 30405135
Oral Oncol. 2018 Jun;81:45-51
pubmed: 29884413
N Engl J Med. 2018 Dec 13;379(24):2342-2350
pubmed: 30280658